Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients

Simone Cesaro, Gloria Tridello, Arcangelo Prete, Sandro Dallorso, Elisa Cannata, Erika Massaccesi, Marco Risso, Massimiliano De Bortoli, Désirée Caselli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. Most of the data on the mobilization efficacy and safety of biosimilar G-CSF are from adult patients, whereas no data are available in pediatric patients. Study Design and Methods: This was a retrospective study on cases treated at three Italian pediatric transplant centers, from January 2011 to October 2013. Data were collected on all children undergoing first peripheral blood stem cell (PBSC) mobilization after stimulation with biosimilar G-CSF and chemotherapy. The results were compared with a historical control group. Results: Twenty-nine children underwent mobilization with biosimilar G-CSF. Peak peripheral blood CD34+ cell count of 20 × 106/L was achieved in 90% of patients, with a median value of 71 × 106/L. Eighty-three percent reached the desired target (CD34+/kg) dose. The median number of collected CD34+ cells was 10 × 106/kg (range, 4.8 × 106-68.8 × 106/kg). No difference was observed in comparison with historical control group mobilized with originator filgrastim. Moreover, no major and/or unexpected side effects were reported. Conclusion: Biosimilar G-CSF resulted as effective and safe as originator filgrastim molecule in mobilizing PBSCs in children, with the advantage of a reduced cost.

Original languageEnglish
Pages (from-to)246-252
Number of pages7
JournalTransfusion
Volume55
Issue number2
DOIs
Publication statusPublished - Feb 1 2015

Fingerprint

Biosimilar Pharmaceuticals
Granulocyte Colony-Stimulating Factor
Hematology
Pediatrics
Hematopoietic Stem Cell Mobilization
Transplants
Control Groups
Blood Cell Count
Hematopoietic Stem Cells
Neutropenia
Blood Cells
Retrospective Studies
Peripheral Blood Stem Cells
Safety
Costs and Cost Analysis
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. / Cesaro, Simone; Tridello, Gloria; Prete, Arcangelo; Dallorso, Sandro; Cannata, Elisa; Massaccesi, Erika; Risso, Marco; De Bortoli, Massimiliano; Caselli, Désirée.

In: Transfusion, Vol. 55, No. 2, 01.02.2015, p. 246-252.

Research output: Contribution to journalArticle

Cesaro, Simone ; Tridello, Gloria ; Prete, Arcangelo ; Dallorso, Sandro ; Cannata, Elisa ; Massaccesi, Erika ; Risso, Marco ; De Bortoli, Massimiliano ; Caselli, Désirée. / Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients. In: Transfusion. 2015 ; Vol. 55, No. 2. pp. 246-252.
@article{76de19597d5d42f8bdda55301669ea14,
title = "Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients",
abstract = "Background: Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. Most of the data on the mobilization efficacy and safety of biosimilar G-CSF are from adult patients, whereas no data are available in pediatric patients. Study Design and Methods: This was a retrospective study on cases treated at three Italian pediatric transplant centers, from January 2011 to October 2013. Data were collected on all children undergoing first peripheral blood stem cell (PBSC) mobilization after stimulation with biosimilar G-CSF and chemotherapy. The results were compared with a historical control group. Results: Twenty-nine children underwent mobilization with biosimilar G-CSF. Peak peripheral blood CD34+ cell count of 20 × 106/L was achieved in 90{\%} of patients, with a median value of 71 × 106/L. Eighty-three percent reached the desired target (CD34+/kg) dose. The median number of collected CD34+ cells was 10 × 106/kg (range, 4.8 × 106-68.8 × 106/kg). No difference was observed in comparison with historical control group mobilized with originator filgrastim. Moreover, no major and/or unexpected side effects were reported. Conclusion: Biosimilar G-CSF resulted as effective and safe as originator filgrastim molecule in mobilizing PBSCs in children, with the advantage of a reduced cost.",
author = "Simone Cesaro and Gloria Tridello and Arcangelo Prete and Sandro Dallorso and Elisa Cannata and Erika Massaccesi and Marco Risso and {De Bortoli}, Massimiliano and D{\'e}sir{\'e}e Caselli",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/trf.12789",
language = "English",
volume = "55",
pages = "246--252",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Blackwell Publishing Inc.",
number = "2",

}

TY - JOUR

T1 - Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients

AU - Cesaro, Simone

AU - Tridello, Gloria

AU - Prete, Arcangelo

AU - Dallorso, Sandro

AU - Cannata, Elisa

AU - Massaccesi, Erika

AU - Risso, Marco

AU - De Bortoli, Massimiliano

AU - Caselli, Désirée

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background: Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. Most of the data on the mobilization efficacy and safety of biosimilar G-CSF are from adult patients, whereas no data are available in pediatric patients. Study Design and Methods: This was a retrospective study on cases treated at three Italian pediatric transplant centers, from January 2011 to October 2013. Data were collected on all children undergoing first peripheral blood stem cell (PBSC) mobilization after stimulation with biosimilar G-CSF and chemotherapy. The results were compared with a historical control group. Results: Twenty-nine children underwent mobilization with biosimilar G-CSF. Peak peripheral blood CD34+ cell count of 20 × 106/L was achieved in 90% of patients, with a median value of 71 × 106/L. Eighty-three percent reached the desired target (CD34+/kg) dose. The median number of collected CD34+ cells was 10 × 106/kg (range, 4.8 × 106-68.8 × 106/kg). No difference was observed in comparison with historical control group mobilized with originator filgrastim. Moreover, no major and/or unexpected side effects were reported. Conclusion: Biosimilar G-CSF resulted as effective and safe as originator filgrastim molecule in mobilizing PBSCs in children, with the advantage of a reduced cost.

AB - Background: Recently biosimilars of granulocyte-colony-stimulating factor (G-CSF) became available for prophylaxis and treatment of postchemotherapy neutropenia and for mobilization of peripheral blood CD34+ cells for either autologous or allogeneic hematopoietic stem cell transplant. Most of the data on the mobilization efficacy and safety of biosimilar G-CSF are from adult patients, whereas no data are available in pediatric patients. Study Design and Methods: This was a retrospective study on cases treated at three Italian pediatric transplant centers, from January 2011 to October 2013. Data were collected on all children undergoing first peripheral blood stem cell (PBSC) mobilization after stimulation with biosimilar G-CSF and chemotherapy. The results were compared with a historical control group. Results: Twenty-nine children underwent mobilization with biosimilar G-CSF. Peak peripheral blood CD34+ cell count of 20 × 106/L was achieved in 90% of patients, with a median value of 71 × 106/L. Eighty-three percent reached the desired target (CD34+/kg) dose. The median number of collected CD34+ cells was 10 × 106/kg (range, 4.8 × 106-68.8 × 106/kg). No difference was observed in comparison with historical control group mobilized with originator filgrastim. Moreover, no major and/or unexpected side effects were reported. Conclusion: Biosimilar G-CSF resulted as effective and safe as originator filgrastim molecule in mobilizing PBSCs in children, with the advantage of a reduced cost.

UR - http://www.scopus.com/inward/record.url?scp=84922966625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922966625&partnerID=8YFLogxK

U2 - 10.1111/trf.12789

DO - 10.1111/trf.12789

M3 - Article

C2 - 25070657

AN - SCOPUS:84922966625

VL - 55

SP - 246

EP - 252

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 2

ER -